Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-2xdlg Total loading time: 0 Render date: 2024-06-23T09:46:33.853Z Has data issue: false hasContentIssue false

154 - Therapy-Induced Cerebral Necrosis (Radiation Necrosis)

from Section 6 - Primarily Intra-Axial Masses

Published online by Cambridge University Press:  05 August 2013

Maria Vittoria Spampinato
Affiliation:
Department of Radiology and Radiological Science, Charleston, SC
Zoran Rumboldt
Affiliation:
Medical University of South Carolina
Zoran Rumboldt
Affiliation:
Medical University of South Carolina
Mauricio Castillo
Affiliation:
University of North Carolina, Chapel Hill
Benjamin Huang
Affiliation:
University of North Carolina, Chapel Hill
Andrea Rossi
Affiliation:
G. Gaslini Children's Research Hospital
Get access

Summary

Specific Imaging Findings

Therapy-induced (radiation) cerebral necrosis (TCN) cannot be reliably differentiated from residual/progressive malignancy on CT or conventional MR imaging. TCN appears as an enhancing mass with surrounding vasogenic edema, frequently increasing in size on serial examinations. Internal irregular linear areas of high T1 signal may be found. Typical patterns of contrast enhancement include internal localized specks of bright signal within necrotic areas (“Swiss cheese/soap bubble” – presumably due to contrast leakage into the cavity) and ill-defined feathery peripheral enhancement (“spreading wavefront”). Edema is limited to the white matter without infiltrative gray matter involvement. On perfusion imaging TCN characteristically shows very low relative cerebral blood volume (rCBV), in contrast to malignant neoplasms. The perfusion signal intensity–time curve shows substantially lower signal recovery than in gliomas, reflecting the high degree of contrast leakage within TCN. Necrosis shows higher signal on ADC maps, compared to relatively low ADC values of viable neoplasms. TCN is characterized by decrease of all metabolites on MR spectroscopy and a dominant very high level of lipids, known as “death peak”.

Pertinent Clinical Information

TCN is a serious complication of radiation therapy for intracranial tumors and non-neoplastic conditions. It also occurs following treatment of extracranial diseases, most notably nasopharyngeal carcinoma. Development of TCN is related to the method of radiation delivery, total dose, fraction size, treatment volume, patient age, and administration of chemotherapy. The changes occur from several months to years after treatment, more frequently following high-dose local radiation, such as radiosurgery or brachytherapy.

Type
Chapter
Information
Brain Imaging with MRI and CT
An Image Pattern Approach
, pp. 319 - 320
Publisher: Cambridge University Press
Print publication year: 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Rogers, LR, Gutierrez, J, Scarpace, L, et al.Morphologic magnetic resonance imaging features of therapy-induced cerebral necrosis. J Neurooncol 2011;101:25–32.CrossRefGoogle ScholarPubMed
2. Barajas RF, Jr, Chang, JS, Segal, MR, et al.Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009;253:486–96.Google Scholar
3. Pruzincova, L, Steno, J, Srbecky, M, et al.MR imaging of late radiation therapy- and chemotherapy-induced injury: a pictorial essay. Eur Radiol 2009;19:2716–27.CrossRefGoogle ScholarPubMed
4. Alexiou, GA, Tsiouris, S, Kyritsis, AP, et al.Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities. J Neurooncol 2009;95:1–11.CrossRefGoogle ScholarPubMed
5. Horky, LL, Hsiao, EM, Weiss, SE, et al.Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. J Neurooncol 2011;103:137–46.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×